Discontinuing GLP-1s may result in the return of appetite and weight gain
The free PDF includes 3 starter days
This model is also satisfying from an evolutionary biology perspective in which GLP-1 and GIP do not have redundant functions in the brain, but rather fit into complimentary niches
Refills' compounding pharmacy partner operates under applicable state and federal pharmacy regulations
Obesity coverage by US payors should increase as prices fall, but in many European countries, particularly Germany, France and Spain, the issue lies with obesity being regarded as a lifestyle disease, and so something that should not be treated with drugs
One promising solution is to pair GLP-1 therapies with agents that block negative muscle regulators like activin receptor type II (ActRII) and ligands such as GDF8 (myostatin) and activin A